Antengene Announces Research Collaboration with Celularity to Evaluate the Potential Therapeutic Synergy of Combining Antengene’s Best-in-Class Bispecific Antibody with Celularity’s Natural Killer Cell Platform

Antengene Corporation Limited announced that it has entered into a pre-clinical research collaboration with Celularity Inc., a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies.